Role of ezetimibe in non-alcoholic fatty liver disease

Table 1 Effects of ezetimibe, alone or combined with other drugs, in non-alcoholic fatty liver disease-related variables in humans

Drug (s)	Parameter
Ezetimibe[16]	↓Visceral fat area
	↓HOMA
	↓Triglycerides, ↓total cholesterol, ↓LDL-C
	↓ALT
	↓hsCRP
	↓Steatosis grade and NAFLD activity score
Ezetimibe plus weight loss[17]	↓Intrahepatic triglyceride content
	↓hsCRP
	↓Interleukin-6
	↓LDL-C
Ezetimibe plus orlistat[20-22]	↓Body mass index and waist circumference
	↓Total cholesterol and triglycerides
	↓HOMA
	↓ALT, AST, γGT

NAFLD: Non-alcoholic fatty liver disease; HOMA: Homeostasis model assessment; LDL-C: Low density lipoprotein cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; γGT: γ-glutamyl-transpeptidase; hsCRP: High sensitivity C-reactive protein.